Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | RAC1 | P63000 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992038 | 0.86 | TRPV1 (0.49) | TRPV1LRRK2MAPK3HIF1AEPAS1 | |
| SCHEMBL14135199 | 0.82 | TRPV1 (0.40) | TRPV1LRRK2HIF1AEPAS1RAC1 | |
| SCHEMBL4360148 | 0.80 | TRPV1 (0.63) | TRPV1MAPK3 | |
| SCHEMBL4993937 | 0.79 | TRPV1 (0.60) | TRPV1MAPK3 | |
| SCHEMBL4971817 | 0.79 | TRPV1 (0.61) | TRPV1MAPK3 | |
| SCHEMBL4986959 | 0.78 | TRPV1 (0.78) | TRPV1MAPK3 | |
| SCHEMBL4989840 | 0.75 | TRPV1 (0.48) | TRPV1LRRK2MAPK3 | |
| SCHEMBL4990699 | 0.73 | TRPV1 (0.54) | TRPV1MAPK3 | |
| SCHEMBL4369914 | 0.72 | TRPV1 (0.66) | TRPV1MAPK3 | |
| SCHEMBL4360072 | 0.71 | TRPV1 (0.65) | TRPV1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080175794-A1 | Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080175794-A1 | Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080175794-A1 | Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175794-A1 | Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues | PIGS, HRH4, GPR68 | TRPV1 199/4885LRRK2 2182/4885MAPK3 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.